ASX:BGTBio-Gene Technology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bio-Gene Technology Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.19 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.19Now: A$0.19▼A$0.1950-Day RangeA$0.13MA: A$0.18▼A$0.2152-Week RangeA$0.08Now: A$0.19▼A$0.32VolumeN/AAverage VolumeN/AMarket Capitalization$25.24 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product chemically synthesized nature-identical compound; and Qcide, a natural oil extracted from the leaves of a rare cultivar of an Australian eucalypt, the Gympie Messmate. The company has research collaborations with contract research organizations, including cesar Pty Ltd and Eurofins to assess Flavocide against a range of mites and insect species; and a research collaboration agreement with James Cook University for the development of a tissue culture system in order to support scale up of future Qcide oil production. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Bio-Gene Technology. Previous Next 2.4 Community Rank Outperform VotesBio-Gene Technology has received 15 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBio-Gene Technology has received 16 “underperform” votes. (Add your “underperform” vote.)Community SentimentBio-Gene Technology has received 51.61% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bio-Gene Technology and other stocks. Vote “Outperform” if you believe BGT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BGT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBio-Gene Technology does not currently pay a dividend.Dividend GrowthBio-Gene Technology does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Gene Technology insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Gene Technology is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Gene Technology is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBio-Gene Technology has a P/B Ratio of 6.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:BGT Previous Symbol CUSIPN/A CIKN/A Webwww.bio-gene.com.au Phone61 3 9628 4178Debt Debt-to-Equity Ratio0.44 Current Ratio8.68 Quick Ratio8.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.07 million Price / Sales23.57 Cash FlowA$0.03 per share Price / Cash Flow7.04 Book ValueA$0.03 per share Price / Book6.13Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares132,867,000Market Cap$25.24 million Next Earnings DateN/A OptionableNot Optionable Receive BGT News and Ratings via Email Sign-up to receive the latest news and ratings for BGT and its competitors with MarketBeat's FREE daily newsletter. Bio-Gene Technology (ASX:BGT) Frequently Asked Questions How has Bio-Gene Technology's stock been impacted by COVID-19 (Coronavirus)? Bio-Gene Technology's stock was trading at A$0.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BGT stock has increased by 35.7% and is now trading at A$0.19. View which stocks have been most impacted by Coronavirus. Has Bio-Gene Technology been receiving favorable news coverage? News headlines about BGT stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bio-Gene Technology earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutBio-Gene Technology. Who are some of Bio-Gene Technology's key competitors? Some companies that are related to Bio-Gene Technology include Predictive Technology Group (PRED), Orgenesis (ORGS), Circassia Pharmaceuticals (CIR), AquaBounty Technologies (AQB), Novoheart (NVH), Immunoprecise Antibodies (IPA), Acasti Pharma (ACST), Omega Diagnostics Group (ORPH), Ampio Pharmaceuticals (AMPE), Ampio Pharmaceuticals (AMPE), Biopharmx (BPMX), Orthocell (OCC), Cynata Therapeutics (CYP), Oxford Biodynamics (OBD) and Pediapharm (PDP). View all competitors. Who are Bio-Gene Technology's key executives? Bio-Gene Technology's management team includes the following people: Mr. Richard Jagger BSC (HONS), M.INTL.BUS, GAICD, MD, CEO & DirectorMr. Roger McPherson B.Bus, CPA, GAICD, CFO & Company Sec.Mr. Peter Donald May, Exec. Director of R&D and Director What is Bio-Gene Technology's stock symbol? Bio-Gene Technology trades on the ASX under the ticker symbol "BGT." What is Bio-Gene Technology's stock price today? One share of BGT stock can currently be purchased for approximately A$0.19. How big of a company is Bio-Gene Technology? Bio-Gene Technology has a market capitalization of $25.24 million and generates $1.07 million in revenue each year. What is Bio-Gene Technology's official website? The official website for Bio-Gene Technology is www.bio-gene.com.au. How can I contact Bio-Gene Technology? The company can be reached via phone at 61 3 9628 4178. This page was last updated on 6/4/2020 by MarketBeat.com Staff
